All In Biotech

Drug Trial Radar · NCT00492986

An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma

An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients With Advanced Renal Cell Carcinoma

Last checked: Nov 20, 2026Latest source record: Dec 30, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,150

Actual

Start

Oct 2005

Primary completion

Nov 2008

Study completion Nov 2008

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Jun 27, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Purpose of the study: The purpose of this study is to make sorafenib available for patients with advanced Renal Cell Carcinoma, who have failed prior systemic therapy for advanced disease (i.e. requiring second line treatment), and who do not have access to or are not eligible for other clinical trials with sorafenib and who may benefit from treatment with sorafenib. Patients will be treated orally with 400 mg bid sorafenib on a continuous basis and as a single agent. Patients may continue treatment until Disease Progression, intolerable toxicity, the patients chooses to withdraw consent or the patient is unlikely to benefit any further from treatment. Overall, participation in the study will help determine the following: * Find out if patients receiving Sorafenib will live longer * Find out if Sorafenib helps to slow the worsening of kidney cancer * Find out if Sorafenib has an effect on the tumours

Conditions

  • Carcinoma, Renal Cell

Interventions

  • Nexavar (Sorafenib, BAY43-9006)Drug

    Multikinase inhibitor: Sorafenib mono therapy 400 mg bid

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety ParametersTime frame: Continously

Locations

33 sites in 11 countries. Site status is shown where the registry gives one.

  • Site not named

    Bruxelles - Brussel, Belgium

  • Site not named

    Leuven, Belgium

  • Site not named

    Århus C, Denmark

  • Site not named

    Bordeaux, France

  • Site not named

    Lyon, France

  • Site not named

    Villejuif, France

  • Site not named

    München, Bavaria, Germany

  • Site not named

    Hamburg, Free and Hanseatic City of Hamburg, Germany

  • Site not named

    Darmstadt, Hesse, Germany

  • Site not named

    Düsseldorf, North Rhine-Westphalia, Germany

  • Site not named

    Koblenz, Rhineland-Palatinate, Germany

  • Site not named

    Mainz, Rhineland-Palatinate, Germany

  • Site not named

    Homburg, Saarland, Germany

  • Site not named

    Dresden, Saxony, Germany

  • Site not named

    Lübeck, Schleswig-Holstein, Germany

  • Site not named

    Berlin, State of Berlin, Germany

  • Site not named

    Milan, Italy

  • Site not named

    Modena, Italy

  • Site not named

    Pavia, Italy

  • Site not named

    Perugia, Italy

  • Site not named

    Reggio Emilia, Italy

  • Site not named

    Amsterdam, Netherlands

  • Site not named

    Warsaw, Poland

  • Site not named

    Barcelona, Barcelona, Spain

  • Site not named

    Madrid, Madrid, Spain

  • Site not named

    Oviedo, Principality of Asturias, Spain

  • Site not named

    Gothenburg, Sweden

  • Site not named

    Stockholm, Sweden

  • Site not named

    Basel, Canton of Basel-City, Switzerland

  • Site not named

    Geneva, Canton of Geneva, Switzerland

  • Site not named

    London, London, United Kingdom

  • Site not named

    Glasgow, Stratchclyde, United Kingdom

  • Site not named

    Sutton, Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.